Genetic background of high blood pressure is associated with reduced mortality in premature neonates

Wolfgang Göpel,1 Mirja Müller,1 Heike Rabe,2 Johannes Borgmann,1 Tanja Rausch,3 Kirstin Faust,1 Angela Kribs,4 Jörg Dötsch,5 David Ellinghaus,6 Christoph Härtel,1 Claudia Roll,7 Miklos Szabo,8 Peter Nürnberg,9 Andre Franke,6 Inke R König,3 Mark A Turner,10 Egbert Herting1

ABSTRACT
Objective The aim of our study was to determine if a genetic background of high blood pressure is a survival factor in preterm infants.
Design Prospective cohort study.
Setting Patients were enrolled in 53 neonatal intensive care units.
Patients Preterm infants with a birth weight below 1500 g.
Exposures Genetic score blood pressure estimates were calculated based on adult data. We compared infants with high genetic blood pressure estimates (>75th percentile of the genetic score) to infants with low genetic blood pressure estimates (<25th percentile of the genetic score).
Main outcome measures Lowest blood pressure on the first day of life and mortality.
Results 5580 preterm infants with a mean gestational age of 28.1±2.2 weeks and a mean birth weight of 1022±299 g were genotyped and analysed. Infants with low genetic blood pressure estimates had significantly lower blood pressure if compared with infants with high genetic blood pressure estimates (27.3±6.2 vs 27.9±6.4, p=0.009, t-test). Other risk factors for low blood pressure included low gestational age (−1.26 mm Hg/week) and mechanical ventilation (−2.24 mm Hg, p=0.001 for both variables, linear regression analysis).
Mortality was significantly reduced in infants with high genetic blood pressure estimates (28-day mortality: 21/1395, 1.5% vs 44/1395, 3.2%, p=0.005, Fisher’s exact test). This survival advantage was independent of confounders of outcome in preterm infants.
Conclusions Our study provides first evidence that a genetic background of high blood pressure may be beneficial with regard to survival of preterm infants.

INTRODUCTION
In all neonates blood pressure gradually increases during the first weeks of life. In preterm infants, blood pressure at birth is closely related to gestational age.1 Considerable uncertainty exists with regard to the relevance and treatment of low blood pressure.2 In observational studies, low blood pressure is associated with death and other adverse outcomes like intraventricular haemorrhage, periventricular leukomalacia and bronchopulmonary dysplasia.3–6 However, most adverse short-term and long-term outcomes are reported in infants with low blood pressure who were treated with catecholamines.3–8 These data raise the question whether arterial hypotension itself or the treatment of the condition with catecholamines is harmful. Many neonatologists therefore consider low arterial blood pressure not as an indication for urgent medical intervention, if a baby is otherwise stable.8–10 However, experience in adults, children, and several observational studies in preterm infants3,6,11,12 promote a different approach with early volume replacement and intravenous application of catecholamines to prevent prolonged hypotension. As of yet, no large-scale randomised controlled trials of catecholamine treatment in preterm infants have been published.13,14

In adults, blood pressure is in part a heritable trait and the predisposition for high or low blood pressure is randomly inherited at the time of fertilisation. Therefore, genetically determined blood pressure scores are independent from main confounders of outcome in preterm infants. We genotyped a large number of preterm infants for validated genetic polymorphisms influencing blood pressure in adults.15 The aim of our study was to

What is already known on this topic?
- No large-scale randomised trials concerning the treatment of low blood pressure in preterm infants have been published so far.
- Observational data in preterm infants are conflicting since low blood pressure is associated with a number of risk factors for adverse outcomes.

What this study adds?
- A genetic background of high blood pressure was associated with reduced mortality in preterm infants which was not altered by catecholamine therapy.
- Our data give the first evidence that genetic predisposition for high blood pressure is evolutionary beneficial and that current concepts of therapy are not sufficient.
determine if a genetic background of high blood pressure is a survival factor in preterm infants.

**METHODS**

**Study design and participants**

The German Neonatal Network (GNN) collected data in a prospective cohort study. Preterm infants with a birth weight below 1500 g who were admitted to one of the participating study centres were eligible. After informed parental consent, a predefined clinical data set was recorded for each patient. Data quality was ensured by regular onsite monitoring of participating centres. All data were entered in a database by health record administrators at the main GNN office at the University of Lübeck, Germany.

Infants were selected for genetic analysis if chip genotyping data were available and if their maternal descent was European. In multiples, only one infant per twin pair or triplet was selected for the genetic analysis by using the random generator of the ‘R’ statistical computing software. We furthermore excluded infants without recorded lowest blood pressure data on the first day of life and infants with a gestational age above 31 + 6 weeks at birth. All selected infants were enrolled in the GNN between 2009 and 2016. Details of patient selection are given in online supplementary figure 1.

**Exposures**

Published risk factors for low blood pressure in preterm infants include low gestational age, lack of antenatal administration of steroids, mechanical ventilation, multiple birth, emergency caesarean section and 5 min APGAR score below 7.5 6 16 We analysed the effect of these factors on the lowest mean blood pressure levels on day 1 in a linear regression analysis and included the individual gsBP of each infant as a continuous covariate.

Delayed cord clamping and cord milking is also associated with higher blood pressure16 and reduces mortality in preterm infants,17 but was not recorded in the GNN on an individual basis. Therefore, the effect of late cord clamping and cord milking could not be assessed in our study. However, due to site-specific questionnaires we know that about 90% of all newborn intensive care units participating in the GNN do either late cord clamping or cord milking or both.

Birth weight, sex and small for gestational age status (defined as birth weight <10th percentile)18 are reported as descriptive data.

**Genotyping**

Umbilical cord tissue of participating infants was collected after birth and stored at −20°C until transfer to the University of Lübeck. DNA was extracted by standard procedures (Gentra Puregene Tissue Kit, Qiagen, Hilden, Germany). Chip genotyping was done by the Cologne Center for Genomics using ‘Axiom CEU’ (Affymetrix, Santa Clara, California, USA) or the Institute of Clinical Molecular Biology Kiel using ‘Global Screening Array (GSA)’ (Illumina, San Diego, California, USA). After chip genotyping of approximately 500 000 single nucleotide polymorphisms (SNPs) per infant, additional SNPs were imputed. After imputation and quality control, validated SNPs associated with blood pressure in European adults (n=267) were selected.15 Fourteen SNPs were not available in the Axiom-CEU datasets and 16 in the GSA datasets. Two hundred thirty-seven SNPs were available in both datasets and used for this analysis. Many SNPs associated with blood pressure in adults are located close to genes which are expressed in venous or arterial vessels. Expression in cardiopulmonary tissue was less frequently observed.15 Details of selected and excluded SNPs are given in online supplementary table 1. Genetic score blood pressure (gsBP) was calculated based on adult beta estimates according to reference 15 by: gsBP=(gsBP diastolic+gsBP systolic)/2. An example how gsBP scores in preterm infants were calculated is given in online supplementary table 1.

If groups of adults are compared, differences in cumulated beta estimates are closely linked to differences in mean blood pressure (in mm Hg).15 Since mean blood pressure in preterm infants is much lower than in adults, we expected that adult beta estimates will not reflect differences in preterm infants (in mm Hg). Therefore, we compared infants with low genetic beta estimates (gsBP <P25) with infants with high genetic beta estimates (gsBP >P75). Data of infants with intermediate beta estimates (P25–P75) are given as descriptive data only.

**Outcomes**

The only blood pressure recorded in the GNN dataset is the lowest mean blood pressure on the first day of life.4 We compared measured lowest mean blood pressure on the first day of life between infants with low and high genetic beta estimates for blood pressure.

According to our previous publication,4 we selected all-cause mortality during the stay in the hospital as the primary end point of our analysis. We also analysed neonatal mortality (within the first 28 days of life). Common complications of premature birth were analysed as secondary end points. Intraventricular haemorrhage (IVH) was defined as localised bleeding in the germinal matrix (grade I), blood filling up to 50% of a ventricle (grade II), blood filling >50% of a ventricle (grade III) and IVH of any stage with additional periventricular haemorrhagic infarction (grade IV) according to Papile et al.19 Periventricular leukomalacia (PVL) was defined as parenchymal cystic lesions in the periventricular region. Bronchopulmonary dysplasia (BPD) was defined as need of oxygen or respiratory support (continuous positive airway pressure or mechanical ventilation) at 36 + 0 weeks postmenstrual gestational age. Sepsis was defined as blood culture-proven sepsis with at least two clinical signs. Necrotising enterocolitis was defined as necrotising intestinal inflammation requiring surgery. Retinopathy of prematurity (ROP) was defined as ROP requiring treatment. Persistent ductus arteriosus (PDA) was defined as surgical closure of PDA. Missing data were not imputed.

**Statistics**

Data were analysed with SPSS statistics V.25.0 (IBM, New York, USA). The type I error level was set to 0.05. All p values given are two-sided. To test for group differences, we compared infants with low genetic blood pressure estimates (<P25) and infants with high genetic blood pressure estimates by Fisher’s exact test and t-test. To estimate the direct effect of the adult genetic risk score beta estimates on preterm infant blood pressure, we entered crude genetic risk scores beta estimates of preterm infants in a linear regression model including gestational age, lack of antenatal administration of steroids, mechanical ventilation, multiple birth, emergency caesarean section and 5 min APGAR score below 7.

**RESULTS**

A total number of 5580 infants were available for gsBP analysis (see online supplementary figure 1). Preterm infant effect allele frequencies for individual SNPs are given in online supplementary
The main finding of our study is a survival advantage of preterm infants with a genetic background of elevated adult blood pressure. Many of the clinical factors which were associated with high gsBP received less epinephrine. No other differences were observed.

A significantly lower mortality rate was observed in infants with high gsBP. Forty of 1395 (2.9%) infants with high gsBP died compared with 63 of 1395 (4.5%) infants with low gsBP ($p=0.027$, OR 0.62, 95% CI 0.42 to 0.93, Fisher’s exact test). This was in particular due to a reduced mortality within the first 28 days of life (high gsBP: 1.5% vs low gsBP 3.2%, $p=0.005$, OR 0.47, 95% CI 0.28 to 0.79, Fisher’s exact test). Mortality stratified for catecholamine treatment and gsBP is given in figure 1. Infants receiving catecholamines (n=1096) if compared with infants who were not treated with catecholamines had a 20-fold increased mortality within 28 days (9.9% vs 0.5%), and during the stay in the hospital (15.8% vs 0.8%). However, if stratified for gsBP, infants with a predisposition for high gsBP had significantly lower 28 days mortality rates even if treated with catecholamines (figure 1). In a logistic regression analysis with 28-day mortality as dependent variable, lower measured blood pressure on the first day of life and a genetic background of low blood pressure and treatment with catecholamines were associated with higher mortality rates (table 3).

Descriptive data for complications of premature birth are given in table 4. Infants with high gsBP had lower rates of IVH and lower rates of surgery for PDA.

### DISCUSSION

The main finding of our study is a survival advantage of preterm infants with a genetic background of elevated adult blood pressure. Many of the clinical factors which were associated with low gsBP and treatment with catecholamines were associated with reduced blood pressure. Blood pressure on the first day of life and a genetic background associated with reduced blood pressure were the strongest predictors of blood pressure on the first day of life. Antenatal treatment with steroids increased blood pressure in preterm infants on the first day of life, but the effect size was small.

Adult gsBP was significantly associated with blood pressure in preterm infants on the first day of life, but the effect size was small. One mm Hg increase in adult gsBP was associated with a 0.06 mm Hg increased blood pressure in preterm infants on the first day of life (table 2). Treatment with catecholamines stratified to gsBP is given in online supplementary table S3. Infants with high gsBP had lower rates of IVH and lower rates of surgery for PDA.
blood pressure on the first day of life in our study have been reported previously.\textsuperscript{4, 16} Due to the large size of our study, we were able to quantify the combined effects of these factors. These data should be helpful for clinicians who are uncertain if a preterm baby will need (eg, arterial umbilical) lines to monitor and treat low blood pressure.

In our cohort, infants with catecholamine therapy had higher mortality rates when compared with infants without catecholamine therapy, as also reported in other studies.\textsuperscript{20, 21} This might be due to confounding by indication, since drug treatment in our study was not randomised, for example, epinephrine is a standard drug for cardiopulmonary resuscitation. Within the subgroup of infants receiving catecholamine therapy, infants with high genetic blood pressure estimates had a 50% lower mortality rate. This supports the view that genetic predisposition to high blood pressure has only moderate effects on resting blood pressure, but might be lifesaving by enhancing the response to catecholamine therapy in life-threatening situations.

**Table 3** Logistic regression of 28-day mortality

| Exposure                                                                 | Number of infants exposed | Mortality in exposed infants (%) | OR (95% CI) for 28-day mortality in multivariate logistic regression analysis | P value* |
|--------------------------------------------------------------------------|---------------------------|----------------------------------|------------------------------------------------------------------------------|----------|
| All Infants                                                              | 5380                      | 2.4                              | n.a.                                                                         | n.a.     |
| Higher gestational age (per week)                                       | 5380                      | n.a.                             | 0.81 (0.73 to 0.90)                                                          | <0.001   |
| Antenatal treatment with steroids                                       | 4939                      | 2.2                              | 0.66 (0.38 to 1.07)                                                          | 0.15     |
| Measured lowest mean blood pressure on day 1 (per additional mm Hg)     | 5380                      | n.a.                             | 0.96 (0.92 to 0.99)                                                          | 0.038    |
| Genetic score blood pressure >P75                                        | 1340                      | 1.6                              | Ref.                                                                         | Ref.     |
| Genetic score blood pressure P25–P75                                     | 2689                      | 2.4                              | 1.52 (0.90 to 2.68)                                                          | 0.11     |
| Genetic score blood pressure <P25                                        | 1351                      | 3.2                              | 1.20 (1.18 to 3.74)                                                          | 0.012    |
| APGAR score <7 at 5 min                                                  | 959                       | 5.3                              | 1.36 (0.89 to 2.06)                                                          | 0.15     |
| Multiple birth                                                           | 1504                      | 2.9                              | 1.55 (1.02 to 2.35)                                                          | 0.039    |
| Birth by emergency caesarean section                                    | 571                       | 4.0                              | 1.34 (0.79 to 2.29)                                                          | 0.28     |
| Mechanical ventilation on the first day of life                          | 2253                      | 4.6                              | 1.64 (0.97 to 2.76)                                                          | 0.065    |
| Dopamine                                                                 | 512                       | 8.4                              | 0.98 (0.62 to 1.54)                                                          | 0.92     |
| Dobutamine                                                               | 595                       | 9.9                              | 1.18 (1.18 to 2.82)                                                          | 0.007    |
| Norepinephrine                                                           | 299                       | 12.7                             | 1.76 (1.08 to 2.88)                                                          | 0.023    |
| Epinephrine                                                              | 297                       | 23.2                             | 9.90 (6.47 to 15.1)                                                          | <0.001   |

n.a., not available.
Our data furthermore indicate that timing and dosage of current blood pressure treatment is not sufficient for all patients, and that a more personalised approach is needed.

Although inherited factors account for a substantial amount of blood pressure variance (and hypertension), it is still unclear why genetic predisposition for high blood pressure is so frequent in adults. Polymorphisms which were used for calculation and group assignment in our study were identified in a very large genome-wide association study involving >200,000 adults of European descent. In adults, genotypes which are associated with high blood pressure are robust risk factors for negative outcomes including stroke and coronary artery disease. Current concepts assume that a genetic background of high blood pressure is a neutral factor at birth and during early childhood, but results in high incidence of death due to cardiovascular causes later in life. Our data suggest that genetic traits for high blood pressure in adults are also associated with higher blood pressure in very premature infants. It is reasonable to assume that these traits are also associated with higher blood pressure in neonates, raising the question if they have been positively selected during human evolution because they are associated with lower death rates in infancy.

In addition to lower mortality rates, infants with high gsbP had also lower rates of IVH, confirming previous reports that treatment of isolated hypertensin might be helpful to reduce the burden of IVH. It must be emphasised that our data do not provide guidance with regard to intravenous volume therapy and catecholamine therapy itself. Although we observed substantial beneficial effects of genetic predisposition to high blood pressure, it is uncertain how effective blood pressure in preterm infants can be stabilised and if current treatment concepts (ie, early dopamine, dobutamine) have similar effects as genetic predisposition. These important questions can only be solved by adequately powered prospective randomised trials.

Meta-analysis of late cord clamping, which increases intravascular volume after birth, demonstrated a reduced mortality rate in the treatment groups, although a large-scale randomised controlled trial did not find a significant difference for death or major morbidity. These data indicate that a sufficient volume therapy is very important for postnatal stabilisation of preterm infants. However, in the GNN most centres already practice either late cord clamping or cord milking. Despite this fact, infants with a predisposition for higher blood pressures had a survival advantage.

Our study has several limitations. Due to the minimal effect size of each polymorphism, the lack of systolic and diastolic blood pressure levels of infants and the much lower size of our cohort compared with adult datasets, we were not able to test the direct effects of single polymorphisms on blood pressure in preterm infants. This should be done with genome-wide association studies in preterm infants. Ideally, such studies will be able to analyse continuous blood pressure data and more endogenous exposures like cortisol levels and exogenous exposures like catecholamine dosing. This will hopefully result in identification of genetic variants with higher effect size and more specific scores which can be used for therapeutic decisions. Furthermore, our study only included infants of European descent and is therefore not generalisable to other populations. Although our results were unchanged if mothers with preeclampsia were excluded (data not shown), we were not able to test the effect of maternal hypertension, since maternal blood pressure data are not recorded in the GNN. Another limitation of our study is its focus on short-term outcomes. Genetically estimated blood pressure is a lifelong predisposition. Long-term outcome will be interesting, since the benefits of high estimated blood pressure with regard to such an important outcome measure like death suggest that long-term neurodevelopmental outcome of these infants might be superior as well.

Our data support causal protective effects of genetic determination to high blood pressure with regard to mortality in preterm infants. This effect was independent from catecholamine support and occurred within the first 4 weeks of life, suggesting that infants with a predisposition to low blood pressure might benefit from additional medications or altered treatment schedules (ie, personalised therapy). Long-term outcome data are pending. Future randomised controlled trials treating hypotension in preterm infants should consider the genetic predisposition of patients who are enrolled.

Author affiliations
1Paediatrics, University of Lübeck, Lübeck, Germany
2Neonatology, Brighton Sussex University Hospitals NHS Trust, Brighton, UK
3Institute for Medical Biometry and Statistics Lübeck, Lübeck, Germany
4Neonatology and Pediatric Intensive Care, University Hospital of Cologne, Cologne, Germany
5Department of Paediatrics, University of Cologne, Cologne, Germany

Table 4 Mortality and complications of premature birth stratified to genetic score blood pressure (gsBP)

| Low (<25th percentile), n=1395 | Intermediate (25th–75th percentile), n=2790 | High (>75th percentile), n=1395 | OR (95% CI) | P value* Low vs high |
|---|---|---|---|---|---|
| Mortality | 63/1395 (4.5%) | 106/2790 (3.8%) | 40/1395 (2.9%) | 1.60 (1.07–2.40) | 0.027 |
| Mortality within the first 28 days | 44/1395 (3.2%) | 66/2790 (2.4%) | 21/1395 (1.5%) | 2.13 (1.26–3.60) | 0.005 |
| Intraventricular haemorrhage (IVH) | 280/1393 (20.1%) | 149/2798 (17.8%) | 237/1395 (17.0%) | 1.23 (1.02–1.49) | 0.036 |
| IVH grade III or IV | 97/1392 (7.0%) | 174/2787 (6.2%) | 73/1393 (5.2%) | 1.35 (0.99–1.85) | 0.058 |
| Periventricular leukomalacia | 49/1392 (3.5%) | 88/2786 (3.2%) | 50/1392 (3.6%) | 0.98 (0.66–1.46) | 1.000 |
| Bronchopulmonary dysplasia | 270/1394 (19.4%) | 511/2784 (18.4%) | 261/1394 (18.7%) | 1.04 (0.86–1.26) | 0.700 |
| Sepsis | 177/1393 (12.7%) | 338/2785 (12.1%) | 171/1393 (12.3%) | 1.04 (0.83–1.30) | 0.775 |
| Surgery for necrotising enterocolitis | 30/1395 (2.2%) | 71/2790 (2.5%) | 35/1395 (2.5%) | 0.85 (0.52–1.40) | 0.616 |
| Surgery for persistent ductus arteriosus | 73/1395 (5.2%) | 117/2790 (4.2%) | 47/1395 (3.4%) | 1.58 (1.09–2.30) | 0.019 |
| Surgery for retinopathy of prematurity or vascular endothelial growth factor antibodies | 51/1395 (3.7%) | 99/2790 (3.5%) | 43/1395 (3.1%) | 0.70 (0.43–1.14) | 0.463 |

*Two-sided p value comparing groups with low vs high gsbP. Fisher’s exact test was used to compare variables.
Dempsey EM, Al Hazzani F, Barrington KJ. Permissive hypotension in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed 2020;105:F184–F189.

Dempsey EM. Challenges in Treating Low Blood Pressure in Preterm Infants. Children 2015;2:272–88.

Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840–51.

Durrmeyer M, Marchand-Martin L, Porcher R, et al. Abstention or intervention for isolated hypotension in the first 3 days of life in extremely preterm infants: association with short-term outcomes in the EPINEVE 2 cohort study. Arch Dis Child Fetal Neonatal Ed 2017;102:890–6.

Valverde E, Pellicer A, Madero R, et al. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. Pediatrics 2006;117:e1213–e1222.

Barrington K, Brion LP. Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborns. Cochrane Database Syst Rev 2002;3:CD003213.

Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analyses identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet 2017;49:403–15.

Dempsey EM. What should we do about low blood pressure in preterm infants. Neonatology 2017;111:402–7.

Fogarty M, Osborn DA, Askie L, et al. Delayed vs early umbilical cord clamping for preterm infants: a systematic review and meta-analysis. Am J Obstet Gynecol 2018;218:1–8.

Voigt M, Rochow N, Gutmann F, et al. [Birth weight percentile values for girls and boys under consideration of maternal height]. Z Geburtshilfe Neonatol 2012;216:212–9.

Papile LA, Burstein I, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529–34.

Batton B, Li L, Newman NS, et al. Use of antihypotensive therapies in extremely preterm infants. Pediatrics 2013;131:e1865–e1873.

Faranroft JM, Wilson-Costello DE, Newman NS, et al. Treated hypertension is associated with neonatal morbidity and hearing loss in extremely low birth weight infants. Pediatrics 2006;117:1131–5.

Muñoz M, Pong-Wong R, Canela-Xandri O, et al. Evaluating the contribution of genetics and familial shared environment to common disease using the UK Biobank. Nat Genet 2016;48:980–3.

Olsen MH, Angell ST, Asma S, et al. A call to action and a lifestyle strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016;388:2665–712.

Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med 2016;375:2349–58.

Edwards MJ. Genetic selection of embryos that later develop the metabolic syndrome. Med Hypotheses 2012;78:621–5.

Mahoney L, Shah G, Crook D, et al. Literature Review of the Pharmacokinetics and Pharmacodynamics of Dobutamine in Neonates. Pediatr Cardiol 2016;37:14–23.

Dempsey EM, Barrington KJ, Marlow N, et al. Management of hypotension in preterm infants (The HIP Trial): a randomised controlled trial of hypotension management in extremely low gestational age newborns. Neonatology 2014;105:275–81.

Tarnow-Mordi W, Morris J, Kirby A, et al. Delayed versus immediate cord clamping in preterm infants. N Engl J Med 2017;377:2445–55.